Medicines Regulator Launches Investigation into UK Peptide Clinics
The Medicines and Healthcare products Regulatory Agency (MHRA) has initiated an investigation into whether clinics across the United Kingdom are violating legal statutes by promoting unregulated and experimental peptide therapies with unverified health benefits. This probe follows a Guardian investigation that uncovered multiple clinics making potentially unlawful assertions about these substances.
Surge in Interest for Experimental Therapies
In recent years, there has been a significant increase in public interest surrounding peptides for therapeutic applications, ranging from weight management and anti-ageing to enhanced recovery from physical injuries. These compounds are typically administered via injections and have been heavily promoted by sellers, social media influencers, and even some medical professionals, despite a notable lack of robust scientific evidence supporting their efficacy in human subjects.
Most existing studies on peptides have been conducted on animal models or in cellular environments, rather than through comprehensive human clinical trials. The MHRA has clarified that clinics are not authorised to make medicinal claims for peptide treatments offered within their services.
Regulatory Stance and Legal Implications
An MHRA spokesperson emphasised, "If clinics offering peptide injections make medicinal claims for those treatments, the products will be considered medicines and subject to regulation under the Human Medicines Regulations 2012. The MHRA will take action against clinics which are identified as breaching the legal requirements."
However, the Guardian's investigation identified several clinics operating in the UK that provide a variety of unregulated peptides while making extensive claims about their benefits on official websites. For instance, one prominent clinic listed on Google search results advertised Cortexin for neuroprotection and cognitive enhancement, BPC-157 for tissue repair and injury recovery, and Thymosin Alpha for immune system boosting.
After being contacted by the Guardian, this clinic removed these claims from its site. The MHRA confirmed that such assertions constitute medicinal claims and are therefore impermissible.
Clinic Practices and Consumer Guidance
Another top clinic from search results acknowledged on its website that peptides lack large-scale clinical trials and have limited human evidence. Despite this, it advertised seven specific peptides with listed prices and durations of results, all labelled as "research only." The clinic charges £350 per month for a single peptide and £450 for two, offering vials with disposable syringes or pre-loaded injection pens for an additional fee.
During a free consultation with a Guardian reporter, a clinician from this clinic noted that most peptide research is pre-clinical and some peptides remain highly experimental. The clinician highlighted a deficiency in randomised multi-centre clinical trials to assess long-term effects and advised taking breaks of four to eight weeks between usage periods to mitigate risks.
Nevertheless, the clinician recommended two peptides—BPC-157 for post-exercise recovery and MOTS-C for mitochondrial health and energy production—while cautioning against use for individuals who smoke or have a family history of cancer due to potential risks.
Broader Context and Regulatory Framework
Peptides are short chains of amino acids, some of which occur naturally in the body, such as insulin. While approved prescription weight-loss drugs like Wegovy and Mounjaro contain synthetic peptides that have undergone rigorous regulatory scrutiny, many other peptides on the market remain experimental and unregulated.
Lynda Scammell, head of borderline products at the MHRA, stated, "Peptide products may be sold as cosmetics, supplements and medicines, and depending on their intended purpose, they fall under different regulatory frameworks. We disregard claims that products are for 'research purposes' if it is clear that such claims are being used as an attempt to avoid medicines regulations."
The MHRA defines a medicinal product as any substance presented as having properties to prevent or treat disease, which includes injuries or adverse conditions, or to modify physiological functions. The agency assesses each case individually, considering factors like the product's effects and usage patterns.
A clinic spokesperson defended their practices, stating they clearly explain that peptides are not licensed medicines and evidence is largely pre-clinical. They emphasised shared decision-making and noted that many individuals access peptides through unregulated online channels without clinical oversight.
This investigation underscores ongoing concerns about the safety and regulation of emerging therapies in the health and wellness sector.
